{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:07:38Z","timestamp":1792523258153,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"67","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Human papillomavirus (HPV) vaccines received regulatory approval and were recommended for use in young girls nearly 2 decades ago. Uptake is mostly high in resource-rich settings. In resource-limited settings, where the burden of cervical cancer is disproportionately high, access to and uptake of HPV vaccines are nowhere near satisfactory, despite evidence that HPV vaccination is highly cost-effective and a significant value-for-money investment. The discovery that only a single dose of the HPV vaccines may be needed to confer adequate protection may make equitable access to HPV vaccines possible. Indeed, the recent World Health Organization recommendation allowing for 1 or 2 doses is already gaining traction. This monograph aims to update the state of the science related to single-dose HPV vaccine protection and includes both primary data and modeling efforts that address key gaps in the knowledge regarding 1) durability of protection of a single dose of the HPV vaccine, 2) single-dose HPV vaccine effectiveness in both high-income and low-income settings, 3) implementation of single-dose HPV vaccination, and 4) how to accelerate control of cervical cancer by integrating a 1-time screen for cervical disease. The content published in this monograph will continue to advance the science of HPV vaccination and will be vital as new countries make informed decisions about how best to use this remarkable vaccine.<\/jats:p>","DOI":"10.1093\/jncimonographs\/lgae030","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T08:01:31Z","timestamp":1731398491000},"page":"313-316","source":"Crossref","is-referenced-by-count":14,"title":["Single-dose human papillomavirus vaccination: an update"],"prefix":"10.1093","volume":"2024","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6073-2591","authenticated-orcid":false,"given":"Aim\u00e9e R","family":"Kreimer","sequence":"first","affiliation":[{"name":"Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute , Bethesda, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Watson-Jones","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, London School of Hygiene & Tropical Medicine , London,","place":["UK"]},{"name":"Mwanza Intervention Trials Unit, National Institute for Medical Research , Mwanza,","place":["Tanzania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane J","family":"Kim","sequence":"additional","affiliation":[{"name":"Center for Health Decision Science, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dull","sequence":"additional","affiliation":[{"name":"Bill & Melinda Gates Foundation , Seattle, WA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"issue":"2","key":"2025052601263441600_lgae030-B1","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"de Martel","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"3","key":"2025052601263441600_lgae030-B2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025052601263441600_lgae030-B3","doi-asserted-by":"publisher","first-page":"106399","DOI":"10.1016\/j.ypmed.2020.106399","article-title":"HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019","volume":"144","author":"Bruni","year":"2021","journal-title":"Prev Med"},{"issue":"19","key":"2025052601263441600_lgae030-B4","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2025052601263441600_lgae030-B5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/djx158","article-title":"Durability of protection afforded by fewer doses of the HPV16\/18 vaccine: the CVT trial","volume":"110","author":"Safaeian","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"2025052601263441600_lgae030-B6","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/jnci\/djaa011","article-title":"Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial","volume":"112","author":"Kreimer","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2025052601263441600_lgae030-B7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1470-2045(15)00414-3","article-title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","volume":"17","author":"Sankaranarayanan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"2025052601263441600_lgae030-B8","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1038\/s41591-023-02658-0","article-title":"Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results","volume":"29","author":"Barnabas","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"2025052601263441600_lgae030-B9","doi-asserted-by":"publisher","first-page":"e1473","DOI":"10.1016\/S2214-109X(22)00309-6","article-title":"Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial","volume":"10","author":"Watson-Jones","year":"2022","journal-title":"Lancet Glob Health"},{"issue":"10","key":"2025052601263441600_lgae030-B10","doi-asserted-by":"publisher","first-page":"e1485","DOI":"10.1016\/S2214-109X(22)00306-0","article-title":"Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial","volume":"10","author":"Baisley","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2025052601263441600_lgae030-B11","first-page":"645","year":"2022"},{"issue":"9","key":"2025052601263441600_lgae030-B12","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1016\/S1470-2045(15)00229-6","article-title":"Fewer than three doses of HPV vaccine","volume":"16","author":"Jit","year":"2015","journal-title":"Lancet Oncol"},{"issue":"30","key":"2025052601263441600_lgae030-B13","first-page":"26","article-title":"Could 1 dose be less efficacious than 2 doses but still be a great public health intervention?","volume":"1","author":"Kim","journal-title":"HPV World"},{"issue":"32 Pt A","key":"2025052601263441600_lgae030-B14","doi-asserted-by":"publisher","first-page":"4823","DOI":"10.1016\/j.vaccine.2018.04.061","article-title":"Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country","volume":"36","author":"Burger","year":"2018","journal-title":"Vaccine"},{"issue":"32 Pt A","key":"2025052601263441600_lgae030-B15","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.1016\/j.vaccine.2018.02.023","article-title":"Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa","volume":"36","author":"Tan","year":"2018","journal-title":"Vaccine"},{"issue":"11","key":"2025052601263441600_lgae030-B16","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S1470-2045(21)00453-8","article-title":"Vaccine efficacy against persistent human papillomavirus (HPV) 16\/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study","volume":"22","author":"Basu","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"2025052601263441600_lgae030-B17","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/S1470-2045(22)00543-5","article-title":"Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study","volume":"23","author":"Man","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"2025052601263441600_lgae030-B18","doi-asserted-by":"publisher","first-page":"e012580","DOI":"10.1136\/bmjgh-2023-012580","article-title":"Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in India","volume":"8","author":"M de Carvalho","year":"2023","journal-title":"BMJ Glob Health"},{"issue":"10","key":"2025052601263441600_lgae030-B19","doi-asserted-by":"publisher","first-page":"e788","DOI":"10.1016\/S2468-2667(23)00180-9","article-title":"Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis","volume":"8","author":"B\u00e9nard","year":"2023","journal-title":"Lancet Public Health"},{"issue":"10","key":"2025052601263441600_lgae030-B20","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1002\/ijc.34054","article-title":"Now or later: Health impacts of delaying single-dose HPV vaccine implementation in a high-burden setting","volume":"151","author":"Burger","year":"2022","journal-title":"Int J Cancer"},{"issue":"1","key":"2025052601263441600_lgae030-B21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12916-023-02988-3","article-title":"Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis","volume":"21","author":"Prem","year":"2023","journal-title":"BMC Med"},{"issue":"1","key":"2025052601263441600_lgae030-B22","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1186\/s12913-023-10283-3","article-title":"Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: a modelling study","volume":"23","author":"Kiendr\u00e9b\u00e9ogo","year":"2023","journal-title":"BMC Health Serv Res"},{"issue":"29","key":"2025052601263441600_lgae030-B23","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1016\/j.vaccine.2023.05.019","article-title":"Impact, cost-effectiveness, and budget implications of HPV vaccination in Kenya: a modelling study","volume":"41","author":"Mwenda","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"2025052601263441600_lgae030-B24","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2214-109X(22)00475-2","article-title":"Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis","volume":"11","author":"B\u00e9nard","year":"2023","journal-title":"Lancet Glob Health"},{"key":"2025052601263441600_lgae030-B25"},{"issue":"10224","key":"2025052601263441600_lgae030-B26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0140-6736(20)30157-4","article-title":"Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Canfell","year":"2020","journal-title":"Lancet"},{"issue":"10224","key":"2025052601263441600_lgae030-B27","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","article-title":"Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Brisson","year":"2020","journal-title":"Lancet"},{"key":"2025052601263441600_lgae030-B28","article-title":"Evaluating the potential program cost savings with a single-dose HPV vaccination schedule: a modeling study","author":"Slavkovsky","journal-title":"JNCI"},{"issue":"12","key":"2025052601263441600_lgae030-B29","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1038\/s41591-023-02600-4","article-title":"Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population","volume":"29","author":"Simms","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"2025052601263441600_lgae030-B30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.vaccine.2021.11.041","article-title":"Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial","volume":"40","author":"Porras","year":"2022","journal-title":"Vaccine"}],"container-title":["JNCI Monographs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2024\/67\/313\/60629451\/lgae030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2024\/67\/313\/60629451\/lgae030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T05:26:41Z","timestamp":1748237201000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncimono\/article\/2024\/67\/313\/7821484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":30,"journal-issue":{"issue":"67","published-online":{"date-parts":[[2024,11,12]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncimonographs\/lgae030","relation":{},"ISSN":["1052-6773","1745-6614"],"issn-type":[{"value":"1052-6773","type":"print"},{"value":"1745-6614","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,10]]}}}